Skip to main content

Guidance and regulation

Skip to results
377 results sorted by Most viewed
From Medicines and Healthcare products Regulatory Agency (MHRA)
  • How to apply for a clinical trial from 28 April 2026, including eligibility, phases, model IMPDs, costs and how to make changes to your application.

  • Apply for changes to your marketing authorisation, including minor variations type IA and IB, major variations type II and extensions.

  • Guidance on the safe and effective use of GLP-1 medicines for weight loss and diabetes.

  • Information and recommendations for manufacturers on the preparation and presentation of a periodic safety update report (PSUR).

  • How to show the MHRA you're meeting good clinical practice (GCP) standards and what to expect from an inspection.

  • Information and recommendations for approved bodies on the presentation and review of a periodic safety update report (PSUR).

  • The Medicines and Healthcare Regulatory Agency have launched RegulatoryConnect, a service that provides the capability to track applications and view live authorisation details.

  • How to write clear and effective field safety notices (FSNs) for medical devices.

  • Details of the system for reporting adverse drug reactions from medicines or adverse incidents with medical devices in the UK

  • Documentation to support changes made to reporting Manufacturer Incident Reports (MIRs) and Field Safety Corrective Action Reports (FSCAs) to the MHRA following implementation of the Medical Devices (Post-market Surveillance…

  • Pharmacy (P), prescription-only (POM), and general sale list (GSL) medicines: apply to move your medicine to a different classification.

  • A digital platform designed to facilitate the reporting, monitoring, and management of medical device incidents.

  • Guidance on labelling for medicinal products used in clinical trials.

  • Details of the organisations that are currently approved to undertake conformity assessments on medical devices.

  • How to conform with the legal requirements for placing medical devices on the market.

  • The call for application for phase 2 of the AI Airlock is now open. This page contains information on eligibility and how to apply

  • Guidance on manufacturing, importing, distributing and supplying specially manufactured or ordered products, including cannabis-based products for medicinal use in humans (CBPMs), known as 'specials'

  • The Innovative Licensing and Access Pathway (ILAP) is focused on getting the most transformative new medicines to patients in the UK health system more quickly.

  • Guidance on the MHRA’s national assessment procedure for marketing authorisation applications.

  • Information on when software applications (apps) are considered to be a medical device and how they are regulated.